Exopharm Limited appointed Mr. Mark Davies as Chair and Independent Non-Executive Director effective immediately. Mark is Founder and Managing Director at 1861 Capital and has been an investor in Exopharm since the IPO in 2018. Mark has a Bachelor of Commerce from the University of Western Australia and is Non-Executive Chairman of Neurotech International, a drug development company focused on utilising NTI164 in the treatment for paediatric neurological disorders including Autism Spectrum Disorder (ASD).

Mark's appointment to the Board brings further financial and equity capital markets experience to the Company and adds to the appointment of Mr. Clarke Barlow, another financial markets person, to the Board in February 2023. Further to the above, the Company further advises that Mr. Jason Watson has resigned as the Company's inaugural Chair and Independent Non-Executive Director. Jason was appointed Chairman prior to the IPO in 2018 and has helped steer the Company through various stages and challenges since that time.

With these changes the Board will continue to comprise three members, to contain costs whilst maintaining the minimum number - Mark Davies, Clarke Barlow and Ian Dixon.